Literature DB >> 21977881

Is Model for End-Stage Liver Disease score associated with quality of life after liver transplantation?

James R Rodrigue1, David R Nelson, Alan I Reed, Douglas W Hanto, Michael P Curry.   

Abstract

CONTEXT: The Model for End-Stage Liver Disease (MELD) is used to predict short-term mortality of patients on the liver transplant waiting list and to allocate deceased donor livers for transplantation.
OBJECTIVE: To examine the relationship between MELD score before transplant and quality of life and other functional status indicators after transplant. DESIGN, SETTING, AND PATIENTS: Two-hundred sixty-five adults from 2 transplant programs completed quality-of-life measures 1 year after transplantation. A subcohort (n = 115) also completed quality-of-life assessments before transplant. Clinical parameters at the time of transplantation were collected from their medical records. MAIN OUTCOME MEASURES: Short Form-36 Health Survey, version 2; Transplant Symptom Frequency Questionnaire.
RESULTS: Patients with MELD scores greater than 25 at transplantation had significantly higher scores on the Short Form-36 general health (P = .004) and physical component summary (P = .02) than did patients with MELD scores of 25 or less. However, scores on the Transplant Symptom Frequency Questionnaire did not vary significantly by MELD score. Child-Turcotte-Pugh (CTP) score, a measure of disease severity, was significantly associated with total symptom frequency after transplant (P = .03) but was not correlated with any domains on the Short Form-36. In the subcohort of 115 patients, a MELD score greater than 25 at the time of transplantation was associated with greater improvement in physical functioning (11.3 vs 4.8, P = .02), role functioning-physical (10.7 vs 4.7, P = .04), general health (11.9 vs 5.5, P = .03), vitality (10.4 vs 5.2, P = .02), and physical component summary (12.3 vs 5.4, P = .01) relative to patients with MELD scores of 15 to 25.
CONCLUSIONS: The relationship between disease severity before transplant and quality of life after transplant is different depending on the index of disease severity used (MELD vs CTP) and whether the assessment of quality of life is general or specific to transplant-related symptoms.

Entities:  

Mesh:

Year:  2011        PMID: 21977881     DOI: 10.1177/152692481102100305

Source DB:  PubMed          Journal:  Prog Transplant        ISSN: 1526-9248            Impact factor:   1.065


  5 in total

Review 1.  Quality of life, risk assessment, and safety research in liver transplantation: new frontiers in health services and outcomes research.

Authors:  Zeeshan Butt; Neehar D Parikh; Anton I Skaro; Daniela Ladner; David Cella
Journal:  Curr Opin Organ Transplant       Date:  2012-06       Impact factor: 2.640

2.  Health-related quality of life and affective status in liver transplant recipients and patients on the waiting list with low MELD scores.

Authors:  Christian Benzing; Nicco Krezdorn; Julia Förster; Andreas Hinz; Felix Krenzien; Georgi Atanasov; Moritz Schmelzle; Hans-Michael Hau; Michael Bartels
Journal:  HPB (Oxford)       Date:  2016-04-20       Impact factor: 3.647

3.  Predictive accuracy comparison of MELD and Child-Turcotte-Pugh scores for survival in patients underwent TIPS placement: a systematic meta-analytic review.

Authors:  Chunze Zhou; Changlong Hou; Delei Cheng; Wenjing Tang; Weifu Lv
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  Mode of allocation and social demographic factors correlate with impaired quality of life after liver transplantation.

Authors:  Nils Heits; Gunnar Meer; Alexander Bernsmeier; Rainer Guenther; Bjoern Malchow; Thomas Kuechler; Thomas Becker; Felix Braun
Journal:  Health Qual Life Outcomes       Date:  2015-09-30       Impact factor: 3.186

5.  MELD Score Reflects the Mood, Sleep, and Daily Living Ability in Liver Transplantation Candidates: A Descriptive Study.

Authors:  Kaiji Ni; Chenglin Li; Yongbing Qian; Xia Sun; Yan Zhan; Ting Zeng; Siqi Zhu; Qiang Xia; Wei Feng; Yanli Luo
Journal:  Ann Transplant       Date:  2020-12-01       Impact factor: 1.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.